Drilldown: Medicines

Other values:

Search

None (86) · Betapace (1) · Brevibloc (1) · Bystolic (1) · Corgard (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · DXM (1) · DXO (1) · Inderal (1) · Lopressor (tartrate), Toprol XL (succinate) (1) · Spravato (1) · Zebeta (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · None (4) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · NMDA antagonist (3) · Contains LSA (2) · Contains mescaline (2) · NMDA antagonist; sigma receptor agonist (2)

Other values:

Search

None (92) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-000004F5-QINU`"', '"`UNIQ--vote-000004F6-QINU`"', '"`UNIQ--vote-000004F7-QINU`"', '"`UNIQ--vote-000004F8-QINU`"', '"`UNIQ--vote-000004F9-QINU`"' (1) · '"`UNIQ--vote-0000059D-QINU`"' (1) · '"`UNIQ--vote-000005E7-QINU`"', '"`UNIQ--vote-000005E8-QINU`"', '"`UNIQ--vote-000005E9-QINU`"', '"`UNIQ--vote-000005EA-QINU`"', '"`UNIQ--vote-000005EB-QINU`"' (1) · '"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1)

None (92) · 10–40 mg (situational anxiety); 40 mg BID (HTN) (1) · 2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 25–50 mg BID (tartrate); 25–100 mg daily (succinate); 12.5 mg daily in HFrEF (1) · 5 mg daily (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (92) · 10, 20, 40, 60, 80 mg tabs; 60/80/120/160 mg ER caps; 1 mg/mL IV (1) · 2.5, 5, 10, 20 mg tabs (1) · 28 mg/device (each dose uses 2 devices) (1) · 5, 10 mg tabs (1) · Tartrate: 25, 50, 100 mg tabs; 1 mg/mL IV. Succinate ER: 25, 50, 100, 200 mg. (1)

None (92) · 20 mg/d (1) · 40 mg/d (1) · 400 mg/d (1) · 640 mg/d (HTN); 240 mg/d (migraine) (1) · 84 mg per session (1)

None (91) · Intranasal (under direct medical supervision) (1) · IV (2) · Oral (5)

None (91) · 1–2 h (2) · 1–2 h (PO), immediate (IV) (1) · 1–2 h (PO); immediate (IV) (1) · 30–60 minutes (1) · Within hours of first administration (1)

None (91) · 24 h (2) · 6–12 h (IR); 24 h (ER) (1) · 6–12 h (tartrate); 24 h (succinate) (1) · 8–12 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (91) · 3–5 hours (1) · 3–6 h (1) · 3–7 h (1) · 9–12 h (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~7-12 hours (1)

None (91) · 70–90% (oral) (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~25% (extensive hepatic first-pass) (1) · ~48% intranasal (1) · ~50% (1) · ~90% (low first-pass) (1)

None (91) · Avoid; may cause fetal harm (1) · Category C (4) · Not established (1)

None (91) · Rx, Schedule III (US). REMS program required. (1) · Rx-only in US (4) · Schedule I (United States) (1)